Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts

DOI: 10.1007/s00395-012-0249-5
Basic Research in Cardiology, 2012, 107, 249.

#	Paper	IF	Citations
26	Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. *Basic Research in Cardiology*, **2012**, 107, 308	11.8	47
25	Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. *Current Heart Failure Reports*, **2012**, 9, 192-9	2.8	26
24	Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice. *PLoS ONE*, **2012**, 7, e45243	3.7	65
23	Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice. *Free Radical Biology and Medicine*, **2013**, 60, 80-8	7.8	62
22	PKG-1 leucine zipper domain defect increases pulmonary vascular tone: implications in hypoxic pulmonary hypertension. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2014**, 307, L537-44	5.8	14
21	Long term liver specific glucokinase gene defect induced diabetic cardiomyopathy by up regulating NADPH oxidase and down regulating insulin receptor and p-AMPK. *Cardiovascular Diabetology*, **2014**, 13, 24	8.7	7
20	Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative stress and altered contractile protein expression. *Journal of Biological Chemistry*, **2014**, 289, 4145-60	5.4	107
19	Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1 signaling. *American Journal of Physiology - Heart and Circulatory Physiology*, **2014**, 306, H1558-68	5.2	61
18	Preventive effect of phosphodiesterase 5 inhibitor tadalafil on experimental post-pyelonephritic renal injury in rats. *Journal of Surgical Research*, **2014**, 186, 253-61	2.5	9
17	PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. *Pharmacology & Therapeutics*, **2015**, 147, 12-21	13.9	144
16	A Combination of Leucine, Metformin, and Sildenafil Treats Nonalcoholic Fatty Liver Disease and Steatohepatitis in Mice. *International Journal of Hepatology*, **2016**, 2016, 9185987	2.7	17
15	Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases. *Journal of Medicinal Chemistry*, **2016**, 59, 10411-10434	8.3	29
14	Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential. *Expert Review of Proteomics*, **2016**, 13, 857-71	4.2	9
13	Tadalafil reduces airway hyperactivity and protects against lung and respiratory airways dysfunction in a rat model of silicosis. *International Immunopharmacology*, **2016**, 40, 530-541	5.8	23
12	Phosphodiesterase 5 Associates With 2 Adrenergic Receptor to Modulate Cardiac Function in Type 2 Diabetic Hearts. *Journal of the American Heart Association*, **2019**, 8, e012273	6	17
11	Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NS-0200) on Weight and Metabolic Parameters. *Obesity*, **2019**, 27, 59-67	8	13
10	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. *British Journal of Pharmacology*, **2020**, 177, 5467-5488	8.6	34

9	PDE5 Inhibitors in Type 2 Diabetes Cardiovascular Complications. *Endocrines*, **2020**, 1, 90-101	0.8	2
8	Chronic inhibition of phosphodiesterase 5 with tadalafil affords cardioprotection in a mouse model of metabolic syndrome: role of nitric oxide. *Molecular and Cellular Biochemistry*, **2020**, 468, 47-58	4.2	7
7	Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. *Diabetes/Metabolism Research and Reviews*, **2021**, e3494	7.5	6
6	Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities. *Pharmacology & Therapeutics*, **2021**, 226, 107858	13.9	2
5	Leucine and Sildenafil Combination Therapy Reduces Body Weight and Metformin Enhances the Effect at Low Dose: A Randomized Controlled Trial. *American Journal of Therapeutics*, **2021**, 28, e1-e13	1	2
4	PDE-5 Inhibitors in Protection of Diabetic Heart. **2014**, 323-338		
3	First molecular modelling report on tri-substituted pyrazolines as phosphodiesterase 5 (PDE5) inhibitors through classical and machine learning based multi-QSAR analysis. *SAR and QSAR in Environmental Research*, **2021**, 32, 917-939	3.5	1
2	Efeito cardioprotetor dos inibidores da Fosfodiesterase 5 em modelo de Diabetes Mellitus experimental. *ABCS Health Sciences*,	0.6	
1	Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine□□possible prevention strategy for COVID-19?.		0